Navigating the Regulatory and Scientific Complexities of Combination Therapy Protocols

By Marta Mas
Executive Director, Medical Writing

Combination therapies are redefining how complex diseases are treated, but they also introduce a new level of scientific, regulatory, and documentation complexity. With multiple mechanisms of action, overlapping safety considerations, and evolving regulatory expectations, combination therapy trials demand exceptional clarity, precision, and consistency in clinical trial protocols.

As the volume of combination therapy studies continues to rise across oncology, immunology, and other complex indications, protocol quality has become a critical success factor. Poorly structured or unclear protocols can lead to misalignment across stakeholders, protocol amendments, delayed approvals, and increased risk to patients and data integrity.

This white paper offers an expert medical writing perspective on developing high-quality, regulatory-compliant protocols for combination therapy trials. Authored by Marta Mas, Executive Director of Medical Writing at TFS HealthScience, it draws on decades of experience translating complex scientific concepts into clear, actionable clinical documentation that supports efficient trial execution and regulatory review.

Inside, you’ll discover:

  • How different types of combination therapies introduce unique protocol design and documentation challenges
  • Best practices for structuring combination therapy protocols to improve clarity, consistency, and regulatory readiness
  • The critical role of medical writers in aligning scientific intent, statistical design, and regulatory expectations
  • Key considerations for risk–benefit analysis, informed consent, and safety monitoring in multi-intervention trials
  • How emerging tools, including AI and digital technologies, are influencing the future of protocol development

Download the white paper to gain a medical writing–led perspective on navigating the regulatory and scientific complexities of combination therapy protocols, and learn how stronger documentation can set combination trials up for success.

Learn more about our related services and resources:

TFS Medical Writing

Download the White Paper

Marta Mas, Executive Director of Medical Writing at TFS

About the Author

Marta Mas

Marta Mas is a Medical Doctor and Specialist in Clinical Pharmacology with over 25 years of experience in clinical research and drug development across academic and pharmaceutical industry settings.

Connect with Us

Contact us today to discover how TFS can be your strategic CRO partner in clinical development.

Let's Talk

Learn More About Our Medical Writing Expertise

Navigating the Regulatory and Scientific Complexities of Combination Therapy Protocols
Navigating the Regulatory and Scientific Complexities of Combination Therapy ProtocolsWhite paper

Navigating the Regulatory and Scientific Complexities of Combination Therapy Protocols

Combination therapy trials require clear, compliant protocols to manage complexity and risk. Download our white paper for expert medical writing insights on effective protocol development.
Top 10 CROs to watch in 2025
Top 10 Contract Research Organizations (CROs) for 2025Article

Top 10 Contract Research Organizations (CROs) for 2025

Discover the top 10 CROs in 2025. Learn about industry leaders in clinical trials, technology adoption, & global healthcare solutions.
A group photo of TFS's medical writing team leaders.
TFS HealthScience’s Medical Writing Team: Champions of Clarity and ComplianceArticle

TFS HealthScience’s Medical Writing Team: Champions of Clarity and Compliance

Explore how TFS HealthScience's Medical Writing Team excels in creating clear, compliant documents, supporting pharmaceutical and biotech companies in bringing innovative treatments to market.